This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peden, C. S.
Right arrow Articles by Mandel, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peden, C. S.
Right arrow Articles by Mandel, R. J.

 Previous Article  |  Next Article 

Journal of Virology, June 2004, p. 6344-6359, Vol. 78, No. 12
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.12.6344-6359.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain

Carmen S. Peden,1,2,3 Corinna Burger,2,3,4 Nicholas Muzyczka,2,3,4 and Ronald J. Mandel1,2,3*

Department of Neuroscience,1 Department of Molecular Genetics and Microbiology,3 Powell Gene Therapy Center,2 McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida4

Received 25 November 2003/ Accepted 13 February 2004

Epidemiological studies report that 80% of the population maintains antibodies (Ab) to wild-type (wt) adeno-associated virus type 2 (AAV2), with 30% expressing neutralizing Ab (NAb). The blood-brain barrier (BBB) provides limited immune privilege to brain parenchyma, and the immune response to recombinant AAV (rAAV) administration in the brain of a naive animal is minimal. However, central nervous system transduction in preimmunized animals remains unstudied. Vector administration may disrupt the BBB sufficiently to promote an immune response in a previously immunized animal. We tested the hypothesis that intracerebral rAAV administration and readministration would not be affected by the presence of circulating Ab to wt AAV2. Rats peripherally immunized with live wt AAV2 and naive controls were tested with single intrastriatal injections of rAAV2 encoding human glial cell line-derived neurotrophic factor (GDNF) or green fluorescent protein (GFP). Striatal readministration of rAAV2-GDNF was also tested in preimmunized and naive rats. Finally, serotype specificity of the immunization against wt AAV2 was examined by single injections of rAAV5-GFP. Preimmunization resulted in high levels of circulating NAb and prevented transduction by rAAV2 as assessed by striatal GDNF levels. rAAV2-GFP striatal transduction was also prevented by immunization, while rAAV5-GFP-mediated transduction, as assessed by stereological cell counting, was unaffected. Additionally, inflammatory markers were present in those animals that received repeated administrations of rAAV2, including markers of a cell-mediated immune response and cytotoxic damage. A live virus immunization protocol generated the circulating anti-wt-AAV Ab seen in this experiment, while human titers are commonly acquired via natural infection. Regardless, the data show that the presence of high levels of NAb against wt AAV can reduce rAAV-mediated transduction in the brain and should be accounted for in future experiments utilizing this vector.

* Corresponding author. Mailing address: University of Florida College of Medicine, P.O. Box 100244, Gainesville, FL 32610. Phone: (352) 294-0446. Fax: (352) 392-8347. E-mail: rmandel{at}ufl.edu.

Journal of Virology, June 2004, p. 6344-6359, Vol. 78, No. 12
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.12.6344-6359.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Puntel, M., Barrett, R. J., Mondkar, S., Saxena, V., Kroeger, K. M., Muhammad, A. K. M., Liu, C., Bondale, N., Sciascia, S., Xiong, W., Shi, Y., Salem, A., Zadmehr, A., Huynh, P., Palmer, D., Ng, P., Castro, M. G., Lowenstein, P. R. (2009). Herpes Simplex Virus Type 1 Thymidine Kinase Sequence Fused to the lacZ Gene Increases Levels of {beta}-Galactosidase Activity per Genome of High-Capacity but Not First-Generation Adenoviral Vectors In Vitro and In Vivo. J. Virol. 83: 2004-2010 [Abstract] [Full Text]  
  • Negrete, A., Kotin, R. M. (2008). Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct Genomic Proteomic 0: eln034v1-eln034 [Abstract] [Full Text]  
  • Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., Muruve, D. A. (2008). Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors. J. Virol. 82: 2727-2740 [Abstract] [Full Text]  
  • Lyon, A R, Sato, M, Hajjar, R J, Samulski, R J, Harding, S E (2008). Gene therapy: targeting the myocardium. Heart 94: 89-99 [Abstract] [Full Text]  
  • Adriaansen, J., Vervoordeldonk, M. J. B. M., Tak, P. P. (2006). Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668 [Abstract] [Full Text]  
  • Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A. (2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80: 2621-2630 [Abstract] [Full Text]  
  • Lochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., Colosi, P. (2006). Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization. J. Virol. 80: 821-834 [Abstract] [Full Text]  
  • Adriaansen, J, Tas, S W, Klarenbeek, P L, Bakker, A C, Apparailly, F, Firestein, G S, Jorgensen, C, Vervoordeldonk, M J B M, Tak, P P (2005). Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis 64: 1677-1684 [Abstract] [Full Text]  
  • Eslamboli, A., Georgievska, B., Ridley, R. M., Baker, H. F., Muzyczka, N., Burger, C., Mandel, R. J., Annett, L., Kirik, D. (2005). Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease. J. Neurosci. 25: 769-777 [Abstract] [Full Text]  
  • Johnson, P. R., Schnepp, B. C., Connell, M. J., Rohne, D., Robinson, S., Krivulka, G. R., Lord, C. I., Zinn, R., Montefiori, D. C., Letvin, N. L., Clark, K. R. (2005). Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques. J. Virol. 79: 955-965 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»